New combo therapy targets tough lung cancers
NCT ID NCT06868732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug combination (JSKN016 plus other treatments) in 288 people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and to check for side effects. The study is currently recruiting participants in China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat lung cancer
- Can a smartphone app ease the burden of advanced lung cancer?
- Breath of discovery: simple test may sniff out lung cancer
- Acupuncture with a jolt: could needles shield nerves from chemo?
- AI could predict who lives longer after lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study